The PRIM multi-centre study to refine and target early detection in prostate cancer using imaging and biomarkers

Principal Investigator: Vincent Gnanapragasam, Department of Surgery
Co-Investigator:

Funded by: Addenbrooke's Charitable Trust & the CRUK Cambridge Centre Urological Malignancies Programme

The Prostate Health Index, which combines total PSA (tPSA), free PSA and [-2]proPSA, has been shown to outperform tPSA for the prediction of prostate cancer on biopsy. The PRIM study (PHI in Refining MRI) is recruiting in five UK Centres, including the Department of Urology at Cambridge University Hospitals Trust. The study, led by Mr Vincent Gnanapragasam, will determine how the test can be used to reduce and refine the need for expensive imaging tests, such as MRI, while increasing the detection of lethal prostate cancers. The target population is those men with a first referral for suspected new prostate cancer. PRIM represents one of the first multi-centre UK studies to combine a biomarker with modern MR imaging to refine early detection of prostate cancer and applied in real world clinical practice. The study will not only measure overall cancer detection but also the ability of this combination to preferentially detect disease with a poor prognosis using a new prognostic scoring system developed in Cambridge. The results of the first phase of the study will be presented in 2019.